检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:胡晓[1,2] 胡静波[3] 董少华[1,2] 苏卫[3] 陈鹰[1]
机构地区:[1]广州军区武汉总医院,湖北武汉430070 [2]湖北中医药大学,湖北武汉430065 [3]南方医科大学,广东广州510515
出 处:《中国医院药学杂志》2013年第7期543-547,共5页Chinese Journal of Hospital Pharmacy
摘 要:目的:制备复方积雪草苷凝胶膏剂,并考察不同促渗剂对积雪草苷和醋酸曲安奈德体外透皮的影响。方法:采用改良的Franz扩散池研究1%月桂氮芯卓酮,1%丙二醇,0.5%薄荷醇,1%月桂氮芯卓酮+1%丙二醇对积雪草苷和醋酸曲安奈德体外透皮效果的影响,以高效液相(HPLC)法测定积雪草苷及醋酸曲安奈德的含量。结果:积雪草苷体外释放符合Higuchi方程,醋酸曲安奈德体外释放符合零级方程。4组促渗剂对复方积雪草苷凝胶膏剂中积雪草苷促渗能力为1%月桂氮芯卓酮+1%丙二醇>1%月桂氮芯卓酮>0.5%薄荷醇>1%丙二醇,对醋酸曲安奈德促渗能力为1%月桂氮芯卓酮+1%丙二醇>1%月桂氮芯卓酮>1%丙二醇>0.5%薄荷醇。结论:1%月桂氮芯卓酮+1%丙二醇可作为复方积雪草苷凝胶膏剂的促渗剂。OBJECTIVE To prepare compound asiaticoside cataplasm and study the effect of different percutaneous absorption enhancer on its in vitro percutaneous permeability. METHODS A modified Franz diffusion cell device was used to study the effect of 1% azone,0. 5% menthol, 1% 1,2-di-hydroxypropane and 1% azone combined with 1% 1,2-di-hydroxypropane on the in vitro pereutaneous permeability of the compound asiaticoside cataplasm. The contents of aisaticoside and triameinolone acetonide acetate in the modified Franz diffusion cell device were determined by HPLC. RESULTS Transdermal diffusion in vitro of asiaticoside complied with the Higuchi equation. Transdermal diffusion in vitro of triamcinolone acetonide acetate complied with zero order equation. The four penetration enhancers could increase the permeability of the drug. The order of en- hancement for asiaticoside was 1% azone combined with 1% 1,2 di hydroxypropane 〉 1% azone 〉0. 5% menthol〉l% 1,2-di hydroxypropane. The order of enhancement for triamcinolone acetonide acetate was 1% azone combined with 1% 1,2 dihydroxypropane〉1% azone〉1% 1,2-di-hydroxypropane〉0. 5% menthol. CONCLUSION 1% azone combined with 1% 1,2 di hydroxypropane could be used as penetration enhancer of compound asiaticoside cataplasm.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.3